Suppr超能文献

[原发性多汗症患者每日口服7.5毫克奥昔布宁的应用]

[Use of oral oxybutynin at 7.5 mg per day in primary hyperhidrosis].

作者信息

Try C, Messikh R, Elkhyat A, Aubin F, Humbert R P

机构信息

Service de Dermatologie, Hôpital de Besançon, France.

出版信息

Rev Med Liege. 2012 Oct;67(10):520-6.

Abstract

Oxybutynin is being increasingly being prescribed in the treatment of hyperhidrosis but currently, there is no precise dosage for this treatment. Nine patients were treated for primary hyperhidrosis resistant to conventional therapies with oxybutynin between January to May 2010. The treatment was progressively increased at 7.5 mg per day. Oxybutynin efficacy was evaluated by iodine starch test and biometrological measurements at 2 and 4 weeks of treatment. Hyperhidrosis Disease Severity Scale (HDSS) and Dermatology Life Quality Index (DLQI) were obtained for each patient. The means of HDSS and DLQI were respectively 3.2 +/- 0.7 and 17.0 +/- 5.1 before treatment and were 1.8 +/- 0.4 and 4.6 +/- 4.4 at 4 weeks of treatment. Oxybutynin at 7.5 mg per day significantly decreased intensity and area of sweat for palms but not for soles. Trans Epidermal Water Loss, conductance, pH and Skin temperature were modified with treatment. Oxybutynin at 7.5 mg per day has improved patient's quality of life. Efficiency of oxybutynin in primary palmar hyperhidrosis was proved by biometrological measurements and iodine starch test.

摘要

奥昔布宁越来越多地被用于治疗多汗症,但目前对于这种治疗方法尚无精确的剂量。2010年1月至5月期间,9例对传统疗法耐药的原发性多汗症患者接受了奥昔布宁治疗。治疗剂量以每天7.5毫克的幅度逐步增加。在治疗2周和4周时,通过碘淀粉试验和生物计量学测量来评估奥昔布宁的疗效。为每位患者获取多汗症疾病严重程度量表(HDSS)和皮肤病生活质量指数(DLQI)。治疗前HDSS和DLQI的平均值分别为3.2±0.7和17.0±5.1,治疗4周时分别为1.8±0.4和4.6±4.4。每天7.5毫克的奥昔布宁显著降低了手掌出汗的强度和面积,但对脚底无效。治疗改变了经表皮水分流失、电导、pH值和皮肤温度。每天7.5毫克的奥昔布宁改善了患者的生活质量。生物计量学测量和碘淀粉试验证明了奥昔布宁对原发性掌跖多汗症的疗效。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验